Abstract
The activation of signaling pathways mediated by tyrosine kinases contributes to the development and progression of hematological neoplasms, of which we can highlight the BCR-ABL1 (Ph+), JAK2V617F and CSF3RT618I positive myeloproliferative neoplasms (MPN), and the FLT3-ITD positive acute myeloid leukemias (AML). These mutations cause constitutive activation of downstream targets, includin…